

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:sssptal813nrm  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

8/813776

\*\*\*\*\* Welcome to STN International

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Aug 21 CAS patent coverage expanded  
NEWS 3 Aug 24 TABULATE Now Available in More STN Databases  
NEWS 4 Aug 28 MEDLINE from 1958 to Date - Only on STN  
NEWS 5 Sep 7 DGENE GETSIM ALERT: Similarity Current-Awareness  
Searching of Biosequences  
NEWS 6 Sep 11 Textile Technology Digest (TEXTILETECH) now available  
on STN  
NEWS 7 Sep 21 KKF renamed DKILIT  
NEWS 8 Sep 29 The Philippines Inventory of Chemicals and Chemical  
Substances (PICCS) has been added to CHEMLIST  
NEWS 9 Oct 27 New Extraction Code PAX now available in Derwent  
Files  
NEWS 10 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in  
Derwent World Patents Index files  
NEWS 11 Oct 27 Patent Assignee Code Dictionary now available  
in Derwent Patent Files  
NEWS 12 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to  
Derwent Subscriber Files WPIDS and WPIS  
NEWS EXPRESS FREE UPGRADE 5.0DPI FOR STN EXPRESS 5.0 WITH DISCOVER!  
(WINDOWS) NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:02:38 ON 27 NOV 2000

=> file embase medline biosis uspatfull japio wpids caplus agricola lifesci confsci

COST IN U.S. DOLLARS

SINCE FILE ENTRY TOTAL SESSION  
1.05 1.05

FULL ESTIMATED COST

FILE 'EMBASE' ENTERED AT 13:06:46 ON 27 NOV 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:06:46 ON 27 NOV 2000

FILE 'BIOSIS' ENTERED AT 13:06:46 ON 27 NOV 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 13:06:46 ON 27 NOV 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:06:46 ON 27 NOV 2000  
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 13:06:46 ON 27 NOV 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 13:06:46 ON 27 NOV 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 13:06:46 ON 27 NOV 2000

FILE 'LIFESCI' ENTERED AT 13:06:46 ON 27 NOV 2000  
COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'CONFSCI' ENTERED AT 13:06:46 ON 27 NOV 2000  
COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

=> e cavaliere vesely renata maria anna/ai

'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'EMBASE'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'AGRICOLA'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'MEDLINE'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'LIFESCI'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CONFSCI'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'BIOSIS'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CAPLUS'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'USPATFULL'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'WPIDS'  
'AI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'JAPIO'

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> e cavaliere vesely renata maria anna/au

E1	4	CAVALIERE VESELY RENATA/AU
E2	1	CAVALIERE VESELY RENATA MARIA/AU
E3	5 -->	CAVALIERE VESELY RENATA MARIA ANNA/AU
E4	13	CAVALIERE W A/AU
E5	1	CAVALIERE W V R/AU
E6	9	CAVALIERE WILLIAM A/AU
E7	5	CAVALIERE WILLIAM ALBERT/AU
E8	1	CAVALIEREI J/AU
E9	1	CAVALIEREI R/AU
E10	1	CAVALIERI/AU
E11	22	CAVALIERI A/AU
E12	37	CAVALIERI A J/AU

=> s e1-e3

L1 10 ("CAVALIERE VESELY RENATA"/AU OR "CAVALIERE VESELY RENATA MARIA"

=&gt; s l1 and bacteria

L2 8 L1 AND BACTERIA

=&gt; dup rem l2

PROCESSING COMPLETED FOR L2

L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

=&gt; d bib ab 1-7

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS

AN 2000:489149 CAPLUS

TI Beverages containing live lactic **bacteria**IN **Cavaliere, Vesely Renata Maria Anna**; Giani, Giovanni;  
Maiocchi, Gianluigi

PA Sitia-Yomo S.P.A., Italy

SO Eur. Pat. Appl.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1020123	A1	20000719	EP 1999-830013	19990118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

AB The invention relates to beverages for food use in combination with a mixt. of lyophilized live **bacteria** comprising at least three **bacteria** species selected from Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus acidophilus, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecium.

RE.CNT 5

RE

- (1) Cavaliere, V; EP 0555618 A 1993
- (2) Masuda, T; US 5143845 A 1992
- (3) Nestle Sa; EP 0088255 A 1983
- (4) Sitia Yomo Spa; EP 0856259 A 1998
- (5) Yakult Honsha Kk; EP 0529414 A 1993

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2000 ACS

AN 2000:34541 CAPLUS

DN 132:63492

TI Completely natural dessert cream comprising fructooligosaccharides

IN **Cavaliere, Vesely Renata**; Giani, Giovanni; Maiocchi, Gianluigi

PA Sitia-Yomo S.P.A., Italy

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 970618	A1	20000112	EP 1998-830393	19980701
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

AB A natural dessert cream without added sucrose comprises milk, wheat flour, pure milk proteins, .gtoreq.1 natural ingredients selected from egg yolk,

chocolate, cocoa, coffee, natural exts. from vanilla berries, essential lemon oil, hazelnut and almond flavors and fruit of various types, fructose, .gtoreq.1 fructooligosaccharides and optionally live and viable lactic **bacteria** at high concn., milk cream and/or malt. The invention also relates to a process for prepg. said dessert cream.

RE.CNT 29

RE

- (1) Anon; BE 1005438 A 1993
- (2) Anon; CA 2119763 A 1993
- (3) Anon; CA 2119764 A 1993
- (4) Anon; AU 2641692 A 1993
- (5) Anon; AU 2643592 A 1993

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 BIOSIS COPYRIGHT 2000 BIOSIS DUPLICATE 1  
AN 1999:308596 BIOSIS  
DN PREV199900308596  
TI Composition for feed use comprising lyophilized live lactic **bacteria**.  
AU **Cavaliere Vesely, Renata (1)**; Giani, Giovanni; Maiocchi, Gianluigi; Vesely, Marco Emilio; Vesely, Leonardo  
CS (1) Department of Neuroscience, San Raffaele Scientific Institute, Milan Italy  
ASSIGNEE: Sitia-Yomo S.p.A.  
PI US 5895648  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(19-JUL-99) Vol. 1221, No. 3, pp. NO PAGINATION.  
ISSN: 0098-1133.  
DT Patent  
LA English  
AB The invention relates to a composition for feed use containing a mixture of lyophilized live **bacteria** comprising at least two species of **bacteria** selected from Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium bifidum and at least two species of **bacteria** selected from Lactobacillus acidophilus, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus casei,  
Lactobacillus plantarum and Streptococcus faecium and one or more oligosaccharides.

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2000 ACS  
AN 1999:731847 CAPLUS  
TI Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections  
IN **Cavaliere, Vesely Renata Maria Anna**; De, Simone Claudio  
PA Cavaliere Vesely, Renata Maria Anna, Italy; De Simone, Claudio  
SO Eur. Pat. Appl.  
CODEN: EPXXDW

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 956858	A1	19991117	EP 1998-830264	19980430
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 11322621	A2	19991124	JP 1998-352873	19981211
PRAI	EP 1998-830264		19980430		
AB	Use of an assocn. of lactobacilli for prepn. of a pharmaceutical compn. for treatment of vaginosis and vaginitis. Said <b>bacteria</b> assocn. comprises the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, possibly in combination with one or more species selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus cate, Lactobacillus minutus and Lactobacillus				

gasserii. A pharmaceutical compn. comprising said assocn. of lactobacilli adapted for treatment of vaginosis and vaginitis.

L3 ANSWER 5 OF 7 USPATFULL  
AN 1998:14475 USPATFULL  
TI Dietary and pharmaceutical compositions containing lyophilized lactic  
**bacteria**, their preparation and use  
IN **Cavaliere Vesely, Renata Maria Anna**, Via S.Orsola, 11, Milan,  
Italy  
De Simone, Claudio, Via Nuoro, 10, Ardea (Rome), Italy  
PA **Cavaliere Vesely, Renata Maria Anna**, Milan, Italy (non-U.S. individual)  
De Simone, Claudio, Ardea, Italy (non-U.S. individual)  
PI US 5716615 19980210  
AI US 1995-448787 19950524 (8)  
RLI Continuation of Ser. No. US 1993-117751, filed on 8 Sep 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-983839,  
filed on 1 Dec 1992, now abandoned  
PRAI IT 1992-UMI256 19920210  
DT Utility  
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Ware, Deborah K.  
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 772  
AB A pharmaceutical composition containing several different  
**bacteria** including Streptococcus thermophilus, Lactobacilli and  
Bifidobacteria is disclosed. The **bacteria** are present in the  
composition at a total concentration of 1.times.10.sup.11 to  
1.times.10.sup.13 per gram. Further, methods of using the  
pharmaceutical  
are disclosed which include treatment of a gastrointestinal disorder  
and  
hypercholesteremia. Also a method for modulating a host's immune  
response is disclosed.

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2000 ACS

AN 1998:351738 CAPLUS

DN 129:45130

TI Sphingomyelinase compositions and use thereof

IN **Cavaliere Vesely, Renata Maria Anna**; De Simone, Claudio

PA **Cavaliere Vesely, Renata Maria Anna**, Italy; De Simone, Claudio

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9822082	A1	19980528	WO 1997-IT278	19971114
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,				
	JP, KE, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO,				
	NZ, PL, RO, SD, SG, SI, SK, SL, TR, TT, UA, UG, US, UZ, VN, YU,				
	ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	AU 9851340	A1	19980610	AU 1998-51340	19971114
	EP 941056	A1	19990915	EP 1997-946038	19971114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	BR 9713287	A	19991026	BR 1997-13287	19971114
PRAI	IT 1996-RM799		19961122		
	WO 1997-IT278		19971114		
AB	The use of sphingomyelinase to increase the levels of skin and mucosal				

ceramides, as well as dermatol. and cosmetic compns. contg. same which  
are suitable for topical application are disclosed. A lyophilized  
Streptococcus thermophilus suspended in a HEPES buffer was sonicated for  
lysis. The sonicated samples were centrifuged and the supernatant was  
removed to obtain a protein, which was incubated in a buffer contg.  
[N-methyl-14C]sphingomyelin to measure the activity of sphingomyelinase.  
A cream was prepd. contg. sonicated lactic **bacteria** and the  
effect of daily applications of the cream on the ceramide levels of the  
horny layer of the epidermis of the forearm was assayed in volunteers.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2000 ACS

AN 1997:633911 CAPLUS

DN 127:245428

TI Strains of **bacteria** with altered metabolism of bile acids and  
their use

IN **Cavaliere Vesely, Renata Maria**; De Simone, Claudio

PA Cavaliere Vesely, Renata Maria Anna, Italy; De Simone, Claudio

SO Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 795604	A2	19970917	EP 1997-830040	19970205
	EP 795604	A3	19980415		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,				

SE

	CA 2198518	AA	19970911	CA 1997-2198518	19970226
	JP 10000086	A2	19980106	JP 1997-53673	19970307
	CN 1165857	A	19971126	CN 1997-103444	19970310
PRAI	IT 1996-MI468		19960311		

AB Strains of **bacteria** characterized by exhibiting: (a) a  
7.alpha.-dehydroxylase activity of <50%, and (b) a bile acid

deconjugation

activity of <50%, and descendants, mutants, and derivs. thereof

preserving

activities (a) and (b); and a pharmaceutical compn. comprising .gtoreq.1  
such strain useful for preventing and treating diseases assocd. with or  
caused by an altered metab. of bile acids.

=> e vesely renata maria anna cavaliere/au

E1	1	VESELY R M A C V/AU
E2	1	VESELY RENATA/AU
E3	0 -->	VESELY RENATA MARIA ANNA CAVALIERE/AU
E4	1	VESELY RICHARD/AU
E5	33	VESELY RUDOLF/AU
E6	1	VESELY RUDOLF 1884 1966/AU
E7	28	VESELY S/AU
E8	2	VESELY S A/AU
E9	5	VESELY S K/AU
E10	5	VESELY S M/AU
E11	3	VESELY SARA/AU
E12	2	VESELY SARA K/AU

=> s e1 or e2

L4 2 "VESELY R M A C V"/AU OR "VESELY RENATA"/AU

=> d bib ab 1-2

L4 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2000 BIOSIS  
 AN 1993:239536 BIOSIS  
 DN PREV199344112736  
 TI Bacterial translocation and immunological responses in mice  
 monoassociated  
 or biassociated with Lactobacillus bulgaricus and Escherichia coli.  
 AU De Simone, Claudio (1); Salvadori, Bruna Bianchi; Tzantzoglou, Sonia;  
 Jirillo, Emilio; Camaschella, Paolo; Cislighi, Simona; Ciardi, Antonio;  
**Vesely, Renata**  
 CS (1) Cattedra Malattie Infettive, Dip. Medicina Sperimentale, Universita  
 dell'Aquila, I-67100 L'Aquila Italy  
 SO Paubert-Braquet, M. [Editor]; Dupont, C. [Editor]; Paoletti, R. [Editor].  
 (1992) pp. 57-65. Dynamic Nutrition Research, Vol. 1; Foods, nutrition  
 and immunity: Effects of dairy and fermented milk products.  
 Publisher: S. Karger AG P.O. Box, Allschwilerstrasse 10, CH-4009 Basel,  
 Switzerland.  
 Meeting Info.: 2nd Bio-Inova/EIBET Workshop Paris, France December 9,  
 1991  
 ISBN: 3-8055-5605-5.  
 DT Article  
 LA English

L4 ANSWER 2 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
 AN 1999-612820 [53] WPIDS  
 DNC C1999-178593  
 TI Use of Lactobacilli for preparation of medicament for treating vaginosis  
 and vaginitis.  
 DC B04 D16  
 IN DE SIMONE, C; VESELY, R M A C V; CAVALIERE VESELY, R M A;  
 CAVALIERE VED VESELY, R M A  
 PA (DSIM-I) DE SIMONE C; (VESE-I) VESELY R M A C V; (VESE-I) CAVALIERE  
 VESELY  
 R M A; (VESE-I) CAVALIERE VED VESELY R M A  
 CYC 32  
 PI EP 956858 A1 19991117 (199953)\* EN 12p  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 AU 9892400 A 19991111 (200004)  
 JP 11322621 A 19991124 (200006) 8p  
 HU 9802525 A2 19991228 (200010)  
 CN 1233474 A 19991103 (200011)  
 CA 2254548 A1 19991030 (200014) EN  
 BR 9900972 A 20000328 (200029)  
 KR 99083612 A 19991125 (200055)  
 ADT EP 956858 A1 EP 1998-830264 19980430; AU 9892400 A AU 1998-92400  
 19981113;  
 JP 11322621 A JP 1998-352873 19981211; HU 9802525 A2 HU 1998-2525  
 19981103; CN 1233474 A CN 1998-122517 19981119; CA 2254548 A1 CA  
 1998-2254548 19981120; BR 9900972 A BR 1999-972 19990308; KR 99083612 A  
 KR  
 1999-15469 19990429  
 PRAI EP 1998-830264 19980430  
 AB EP 956858 A UPAB: 19991215  
 NOVELTY - Use of an association of lactobacilli of the Lactobacillus  
 brevis and Lactobacillus salivarius subs. salicinius is new for the  
 preparation of a pharmaceutical composition to be employed through  
 vaginal  
 administration for the treatment of vaginosis and vaginitis.  
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a  
 pharmaceutical composition to be used through vaginal administration for  
 the treatment of vaginal infections comprising an association of  
 lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius  
 subs. salicinius species.  
 ACTIVITY - Antiinflammatory; Gynecological.

MECHANISM OF ACTION - None given.

USE - The composition is useful for the treatment of vaginal infections, especially vaginitis and vaginosis (claimed).

ADVANTAGE - The composition efficiently treats vaginal infections at concentrations of 1 multiply 10<sup>6</sup> CFU/g.

Dwg.0/0

=> e desimone claudio/au

E1	4	DESIMONE CHRISTINE/AU
E2	1	DESIMONE CHRISTOPHER P/AU
E3	14 -->	DESIMONE CLAUDIO/AU
E4	40	DESIMONE D/AU
E5	5	DESIMONE D C/AU
E6	7	DESIMONE D J/AU
E7	2	DESIMONE D M/AU
E8	1	DESIMONE D MICHAEL/AU
E9	5	DESIMONE D N/AU
E10	44	DESIMONE D P/AU
E11	93	DESIMONE D W/AU
E12	4	DESIMONE D W */AU

=> s e3

L5 14 "DESIMONE CLAUDIO"/AU

=> s l5 and bacteria

L6 0 L5 AND BACTERIA

=> dup rem l5

PROCESSING COMPLETED FOR L5

L7 14 DUP REM L5 (0 DUPLICATES REMOVED)

=> d ti 1-14

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Carnitine Today.

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Possible anti-apoptotic activity of carnitines on excitatory amino acid-induced neurotoxicity

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Effect of L-carnitine on AZT-induced mitochondrial toxicity: studies on human muscle cultures

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI L-Carnitine, a modulator of immunometabolic homeostasis in subjects infected with the human immunodeficiency virus

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Acylcarnitine and chronic fatigue syndrome

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Involvement of carnitine in Reye's and Reye-like syndromes

L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Carnitine and derivatives in experimental infections

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2000 ACS  
TI Carnitine against ischemia and lipopolysaccharide toxicity



L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI Carnitine deficiency: primary and secondary syndromes

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI Effect of L-carnitine on Fas-induced apoptosis and sphingomyelinase activity in human T cell lines

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI Carnitine and mitochondrial dysfunction

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI Carnitine and myocardial glucose metabolism

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI Molecular biology of carnitine palmitoyltransferases and role of carnitine in gene transcription

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2000 ACS  
 TI The role of carnitine in cell metabolism

=> s bacteria? (5a) strain

L8 20457 BACTERIA? (5A) STRAIN

=> s l8 and gram (5a) positive

L9 2028 L8 AND GRAM (5A) POSITIVE

=> s l9 and deconjugat?

L10 5 L9 AND DECONJUGAT?

=> d bib ab 1-5

L10 ANSWER 1 OF 5 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.  
 AN 1999188456 EMBASE  
 TI Caecal bile acid compositions in gnotobiotic mice associated with human intestinal bacteria with the ability to transform bile acids in vitro.  
 AU Narushima S.; Itoh K.; Kuruma K.; Uchida K.  
 CS K. Itoh, Lab. of Veterinary Public Health, Graduate School of Agric./Life Sci., University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan. akikuji@hongo.ecc.u-tokyo.ac.jp  
 SO Microbial Ecology in Health and Disease, (1999) 11/1 (55-60).  
 Refs: 30  
 ISSN: 0891-060X CODEN: MEHDE6  
 CY Norway  
 DT Journal; Article  
 FS 004 Microbiology  
 048 Gastroenterology  
 LA English  
 SL English  
 AB Germfree mice were orally inoculated with human intestinal bacteria for which the ability to transform bile acids was confirmed by in vitro screening. Three weeks after inoculation, their caecal bile acids were examined. Free-form bile acids were detected in the caecal contents of gnotobiotic mice associated with **deconjugating** bacteria, *Clostridium ramosum* R-18 (above 10%) or extremely oxygen sensitive *Clostridium* M-7 (3.6%). Deoxycholic acid was observed only in the caecal contents of gnotobiotic mice associated with a combination of **deconjugating** and 7.alpha.-dehydroxylating **bacteria**, i. e. **strain** R-18 and *Eubacterium lentum*-like c-25 (4.3%) or a

combination of strain R-18 and unidentified **Gram-positive** rod strain HD-17 (1.1%). 7-Oxo-deoxycholic acid was detected in the caecal contents of gnotobiotic mice associated with strain M-7 (7.alpha.-dehydrogenating in vitro) (1.3%) or strain R-18 plus strain M-7 (2.4%). These results suggest that caecal bile acid composition in gnotobiotic mice reflected the results of bacterial activity in vitro, but bacterial transforming ability itself is insufficient for normal bile acid transformation comparable to that of conventional mice.

L10 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1999:316971 BIOSIS

DN PREV199900316971

TI Caecal bile acid compositions in gnotobiotic mice associated with human intestinal bacteria with the ability to transform bile acids in vitro.

AU Narushima, Seiko; Itoh, Kikuji (1); Kuruma, Kazuo; Uchida, Kiyohisa

CS (1) Laboratory of Veterinary Public Health, Graduate School of Agriculture

and Life Science, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657 Japan

SO Microbial Ecology in Health and Disease, (March, 1999) Vol. 11, No. 1, PP.

55-60.

ISSN: 0891-060X.

DT Article

LA English

SL English

AB Germfree mice were orally inoculated with human intestinal bacteria for which the ability to transform bile acids was confirmed by in vitro screening. Three weeks after inoculation, their caecal bile acids were examined. Free-form bile acids were detected in the caecal contents of gnotobiotic mice associated with **deconjugating** bacteria, *Clostridium ramosum* R-18 (above 10%) or extremely oxygen sensitive *Clostridium* M-7 (3.6%). Deoxycholic acid was observed only in the caecal contents of gnotobiotic mice associated with a combination of **deconjugating** and 7alpha-dehydroxylating **bacteria**, i.e. **strain** R-18 and *Eubacterium lentum*-like c-25 (4.3%) or a combination of strain R-18 and unidentified **Gram-positive** rod strain HD-17 (1.1%). 7-Oxo-deoxycholic acid was detected in the caecal contents of gnotobiotic mice associated with

strain M-7 (7alpha-dehydrogenating in vitro) (1.3%) or strain R-18 plus strain M-7 (2.4%). These results suggest that caecal bile acid composition in gnotobiotic mice reflected the results of bacterial activity in vitro, but bacterial transforming ability itself is insufficient for normal bile acid transformation comparable to that of conventional mice.

L10 ANSWER 3 OF 5 USPATFULL

AN 1998:4454 USPATFULL

TI Lactic acid bacteria of the Genus *Lactobacillus*

IN Saito, Yoshio, Hachioji, Japan

Mizutani, Jun, Sagamihara, Japan

PA Calpis Food Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)

PI US 5707854 19980113

AI US 1995-579573 19951227 (8)

RLI Continuation of Ser. No. US 1995-399209, filed on 6 Mar 1995, now patented, Pat. No. US 5516684

PRAI JP 1994-40921 19940311

DT Utility

EXNAM Primary Examiner: Rollins, John W.; Assistant Examiner: Ware, Deborah K.

LREP Darby & Darby  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 586

AB Lactic acid bacteria of the genus *Lactobacillus* do not exhibit **deconjugation** of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. The particular species of the genus *Lactobacillus* exhibiting these characteristics is *Lactobacillus acidophilus*. Furthermore, the strain *Lactobacillus acidophilus* CL-0062 has been internationally deposited under accession number FERM BP-4980.

L10 ANSWER 4 OF 5 USPTAFULL

AN 96:41124 USPTAFULL  
TI Biologically pure culture of *Lactobacillus acidophilus* FERM-P-14204 or FERM-P-14205  
IN Saito, Yoshio, Hachioji, Japan  
Mizutani, Jun, Sagamihara, Japan  
PA The Calpis Food Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
PI US 5516684 19960514  
AI US 1995-399209 19950306 (8)  
PRAI JP 1994-40921 19940311  
DT Utility  
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Ware, Deborah K.  
LREP Darby & Darby  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 604

AB Lactic acid bacteria of the genus *Lactobacillus* which do not exhibit **deconjugation** of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. There are two specific *Lactobacillus* strains which have been disclosed that exhibit these characteristic properties. The two strains are *Lactobacillus acidophilus* FERM-P-14204 and *Lactobacillus acidophilus* FERM-P-14205.

L10 ANSWER 5 OF 5 LIFESCI COPYRIGHT 2000 CSA

AN 2000:1738 LIFESCI  
TI Caecal bile acid compositions in gnotobiotic mice associated with human intestinal bacteria with the ability to transform bile acids in vitro  
AU Narushima, S.; Itoh, K.\*; Kuruma, K.; Uchida, K.  
CS Laboratory of Veterinary Public Health, Graduate School of Agriculture and Life Science, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan; E-mail: akikuji@hongo.ecc.u-tokyo.ac.jp  
SO Microbial Ecology in Health and Disease [Microb. Ecol. Health Dis.], (19990300) vol. 11, no. 1, pp. 55-60.  
ISSN: 0891-060X.  
DT Journal  
FS J  
LA English  
SL English  
AB Germfree mice were orally inoculated with human intestinal bacteria for which the ability to transform bile acids was confirmed by in vitro screening. Three weeks after inoculation, their caecal bile acids were examined. Free-form bile acids were detected in the caecal contents of gnotobiotic mice associated with **deconjugating** bacteria, *Clostridium ramosum* R-18 (above 10%) or extremely oxygen sensitive *Clostridium* M-7 (3.6%). Deoxycholic acid was observed only in the caecal contents of gnotobiotic mice associated with a combination of **deconjugating** and 7 alpha -dehydroxylating **bacteria**, i. e. strain R-18 and *Eubacterium lentum*-like c-25 (4.3%) or a combination of strain R-18 and unidentified **Gram-**

positive rod strain HD-17 (1.1%). 7-Oxo-deoxycholic acid was detected in the caecal contents of gnotobiotic mice associated with strain M-7 (7 alpha -dehydrogenating in vitro) (1.3%) or strain R-18 plus strain M-7 (2.4%). These results suggest that caecal bile acid composition in gnotobiotic mice reflected the results of bacterial activity in vitro, but bacterial transforming ability itself is insufficient for normal bile acid transformation comparable to that of conventional mice.

=> d his

(FILE 'HOME' ENTERED AT 13:02:38 ON 27 NOV 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA,

LIFESCI, CONFSCI' ENTERED AT 13:06:46 ON 27 NOV 2000

E CAVALIERE VESELY RENATA MARIA ANNA/AU  
L1 10 S E1-E3  
L2 8 S L1 AND BACTERIA  
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)  
E VESELY RENATA MARIA ANNA CAVALIERE/AU  
L4 2 S E1 OR E2  
E DESIMONE CLAUDIO/AU  
L5 14 S E3  
L6 0 S L5 AND BACTERIA  
L7 14 DUP REM L5 (0 DUPLICATES REMOVED)  
L8 20457 S BACTERIA? (5A) STRAIN  
L9 2028 S L8 AND GRAM (5A) POSITIVE  
L10 5 S L9 AND DECONJUGAT?

=> s l9 and dehydrolase

L11 4 L9 AND DEHYDROLASE

=> d bib ab1-4

'AB1-4' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ab

L11 ANSWER 1 OF 4 USPATFULL

AB An aryl acylamidase is produced by a process which comprises culturing in a culture medium an aryl acylamidase-producing **bacterial strain** selected from Rhodococcus erythropolis NCIB 12273 and aryl acylamidase-producing mutants or variants thereof, and collecting aryl acylamidase-containing material.

=> d bib ab 1-4

L11 ANSWER 1 OF 4 USPATFULL

AN 91:54709 USPATFULL  
TI Rhodococcus bacterium for the production of aryl acylamidase  
IN Best, David J., Olney, Great Britain  
Vaughan, Peter A., Oxon, Great Britain  
PA Medisense, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 5030571 19910709  
AI US 1987-79759 19870730 (7)  
PRAI GB 1986-18559 19860730  
DT Utility  
EXNAM Primary Examiner: Rosen, Sam  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1,7,8  
DRWN No Drawings  
LN.CNT 414

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aryl acylamidase is produced by a process which comprises culturing in a culture medium an aryl acylamidase-producing **bacterial strain** selected from *Rhodococcus erythropolis* NCIB 12273 and aryl acylamidase-producing mutants or variants thereof, and collecting aryl acylamidase-containing material.

L11 ANSWER 2 OF 4 USPATFULL

AN 84:25870 USPATFULL  
TI Strain of *Corynebacterium Fascians* and use thereof to reduce limonoid bitterness in citrus products  
IN Hasegawa, Shin, Pasadena, CA, United States  
PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)  
PI US 4447456 19840508  
AI US 1983-456954 19830110 (6)  
DT Utility  
EXNAM Primary Examiner: Golian, Joseph M.; Assistant Examiner: Minnick, Marianne S.  
LREP Silverstein, M. Howard; McConnell, David G.; Connor, Margaret A.  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1,5  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 455

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bitterness in limonoid-containing citrus juice is reduced by treatment with a novel strain of *Corynebacterium fascians* having the capability of producing enzymes for metabolizing limonoids without the presence of a limonoid inducer in the growth medium.

L11 ANSWER 3 OF 4 USPATFULL

AN 80:48429 USPATFULL  
TI Antibiotic SB-72310  
IN Imada, Akira, Nishinomiya, Japan  
Kintaka, Kazuhiko, Takatsuki, Japan  
Haibara, Konomi, Osaka, Japan  
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 4225586 19800930  
AI US 1978-971090 19781215 (5)  
PRAI JP 1978-122277 19781003  
DT Utility  
EXNAM Primary Examiner: Goldberg, Jerome D.  
LREP Wenderoth, Lind & Ponack  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel Antibiotic SB-72310 is produced by cultivating a microorganism belonging to the genus *Pseudomonas* and being capable of producing Antibiotic SB-72310 in a culture medium to have Antibiotic SB-72310 elaborated and accumulated in the cultured broth and recovering the antibiotic.

Antibiotic SB-72310 is useful as a germicide or disinfectant.

AN 2000-146307 [13] WPIDS

DNC C2000-045656

TI Strain pseudomonas batumici novum species 3187 produces antibiotic showing

antistaphylococcus activity.

DC B04 D16

IN BOIKO, O I; ESIPOV, S E; KIPRIANOVA, E A

PA (ASMI-R) AS USSR MICROORGANISMS BIOCHEM PHYSIOLOGY; (MICR-R) MICROBIOL VIROLOGY INST

CYC 1

PI SU 598368 A3 19981010 (200013)\*

ADT SU 598368 A3 SU 1976-2385785 19760719

PRAI SU 1976-2385785 19760719

AB SU 598368 A UPAB: 20000313

NOVELTY - Pseudomonas batumici nov. sp. 3187 as a producer of antibiotic showing antistaphylococcus activity. Strain is stored in Collection of Microbiology and Virology Institute of Academy of Sciences of the Ukraine at number 3187.

DETAILED DESCRIPTION - Invention relates to the strain Pseudomonas batumici nov. sp. 3187 as a producer of antibiotic showing antistaphylococcus activity. Strain is stored in Collection of Microbiology and Virology Institute of Academy of Sciences of the Ukraine at number 3187.

Cultural-morphological characters: cells of the strain are **gram-positive** rods (size is 2.2 x 1.0 mcm), mobile, have two polar flagelli (length is an average 6-8 mcm), coil number is 4-6. Strain does not form inclusions of poly- beta -hydroxybutyric acid. Cells grow well on usual nutrient media:

(i) On beef-extract agar: colonies are round, smooth, bright, layer-like.

(ii) On beef-extract broth: uniform turbidity, yellow-green fluorescent pigment is not formed.

(iii) On glucose medium: cells form yellow-brown pigment diffusing in medium that can be extracted with chloroform.

Colonies are stained with yellow-brown color, being more dark than medium. Physiological-biochemical characters: strain is restrict aerobe, uses glucose by oxidative way only.

Strain has activities of oxidase, arginine **dehydrolase**, levansaccharase and decitinase but does not reduce nitrates and does not hydrolyze gelatin and esculin. Strain does not oxidase gluconate and does not convert quinic acid to protocatechuic acid. Optimal growth

temperature

is 27 C, very weak growth - at 37 deg. C and no growth at 42 deg. C.

Strain assimilates ammonium and nitrate forms of nitrogen and shows sensitivity to nitrofurantoin. Strain uses D-galactose, L-arabinose, D-mannose, fructose, trehalose, gluconate, acetic, malonic, succinic, maleic, fumaric, glutaric, lactic, isocitric, citric, aconitic, oxaloacetic, itaconic, malic, aspartic, glutamic, gamma -aminobutyric and quinic acids, mannitol, inositol, glycerol, alpha -alanine, beta

-alanine,

isoleucine, valine, arginine, ornithine, citrulline, betaine, sarcosine

as

a single carbon source. Strain does not use aliphatic alcohols, fatty acids and aromatic compounds. Antagonistic properties: strain shows activity with respect to Staphylococcus aureus, Erwinia aroideae, phytopathogenic species Pseudomonas, Xanthomonas campestris and Xanthomonas malvacearum and inhibits partially the growth of Escherichia coli, Bacillus subtilis, Corynebacterium michiganense, Agrobacterium tumefaciens but does not show antagonistic activity with respect to

yeasts

and fungi.

USE - Microbiology, biotechnology.

=> d his

(FILE 'HOME' ENTERED AT 13:02:38 ON 27 NOV 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA,

LIFESCI, CONFSCI' ENTERED AT 13:06:46 ON 27 NOV 2000

E CAVALIERE VESELY RENATA MARIA ANNA/AU

L1 10 S E1-E3

L2 8 S L1 AND BACTERIA

L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

E VESELY RENATA MARIA ANNA CAVALIERE/AU

L4 2 S E1 OR E2

E DESIMONE CLAUDIO/AU

L5 14 S E3

L6 0 S L5 AND BACTERIA

L7 14 DUP REM L5 (0 DUPLICATES REMOVED)

L8 20457 S BACTERIA? (5A) STRAIN

L9 2028 S L8 AND GRAM (5A) POSITIVE

L10 5 S L9 AND DECONJUGAT?

L11 4 S L9 AND DEHYDROLASE

=> s l9 and (streptococcus or lactobacillus)

L12 689 L9 AND (STREPTOCOCCUS OR LACTOBACILLUS)

=> s l12 and bile acid

L13 5 L12 AND BILE ACID

=> d bib ab 1-5

L13 ANSWER 1 OF 5 USPATFULL

AN 1998:4454 USPATFULL

TI Lactic acid bacteria of the Genus **lactobacillus**

IN Saito, Yoshio, Hachioji, Japan

Mizutani, Jun, Sagamihara, Japan

PA Calpis Food Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)

PI US 5707854 19980113

AI US 1995-579573 19951227 (8)

RLI Continuation of Ser. No. US 1995-399209, filed on 6 Mar 1995, now patented, Pat. No. US 5516684

PRAI JP 1994-40921 19940311

DT Utility

EXNAM Primary Examiner: Rollins, John W.; Assistant Examiner: Ware, Deborah K.

LREP Darby & Darby

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 586

AB Lactic acid bacteria of the genus **Lactobacillus** do not exhibit deconjugation of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. The particular species of the genus **Lactobacillus** exhibiting these characteristics is **Lactobacillus acidophilus**. Furthermore, the strain **Lactobacillus acidophilus** CL-0062 has been internationally deposited under accession number FERM BP-4980.

L13 ANSWER 2 OF 5 USPATFULL  
AN 96:41124 USPATFULL  
TI Biologically pure culture of **Lactobacillus acidophilus**  
FERM-P-14204 or FERM-P-14205  
IN Saito, Yoshio, Hachioji, Japan  
Mizutani, Jun, Sagamihara, Japan  
PA The Calpis Food Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
PI US 5516684 19960514  
AI US 1995-399209 19950306 (8)  
PRAI JP 1994-40921 19940311  
DT Utility  
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Ware, Deborah K.  
LREP Darby & Darby  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 604  
AB Lactic acid bacteria of the genus **Lactobacillus** which do not exhibit deconjugation of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. There are two specific **Lactobacillus** strains which have been disclosed that exhibit these characteristic properties. The two strains are **Lactobacillus acidophilus** FERM-P-14204 and **Lactobacillus acidophilus** FERM-P-14205.

L13 ANSWER 3 OF 5 USPATFULL  
AN 94:88630 USPATFULL  
TI **Lactobacillus casei** (BP-4442)  
IN Hashimoto, Hideo, Yokohama, Japan  
Ito, Hayami, Himeji, Japan  
PA Japanese Research & Development Association For New Food Materials, Japan (non-U.S. corporation)  
PI US 5354687 19941011  
AI US 1993-24087 19930301 (8)  
PRAI JP 1992-4075622 19920227  
DT Utility  
EXNAM Primary Examiner: Marx, Irene; Assistant Examiner: Sevingny, Jeffrey J.  
LREP Wigman, Cohen, Leitner & Myers  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 311

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein is a bacterium having high antimutagenicity against mutagens and belonging to the genus of **Lactobacillus**. The mutagens may comprise both a base-pair change mutagen and a frameshift mutagen. The bacterium preferably has high intestine reachability and can be **Lactobacillus casei**.

L13 ANSWER 4 OF 5 USPATFULL  
AN 94:86182 USPATFULL  
TI Method for preparing vaccine for dental caries and vaccinal compositions  
for dental caries used as nasal drop  
IN Koga, Toshihiko, Tokyo, Japan  
Okahashi, Nobuo, Komae, Japan  
Takahashi, Ichiro, Yokohama, Japan  
Shibuya, Koji, Kanagawa, Japan  
Ohta, Hirotaka, Kanagawa, Japan  
PA Lion Corporation, Tokyo, Japan (non-U.S. corporation)  
National Institute of Health, Tokyo, Japan (non-U.S. corporation)  
PI US 5352450 19941004  
AI US 1990-529602 19900529 (7)  
PRAI JP 1989-1137025 19890529  
JP 1989-1207700 19890809



DT Utility  
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Sidberry, Hazel F.  
LREP Burns, Doane, Swecker & Mathis  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 910  
AB A method for preparing a vaccine for dental caries comprises the step of  
culturing a variant which is obtained by integrating a protein antigen (Pac)-expressing gene into the chromosomal gene of a **Streptococcus** mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of oral **Streptococcus** mutans or it being extracellularly produced by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. **Streptococcus** mutans GS-5 (K-3), in which a protein antigen-expressing gene is integrated into the chromosomal gene thereof, has an ability of producing the protein antigen on the surface of the cells or extracellularly. A preventive vaccine composition for dental caries for nasal drops comprises the protein antigen thus produced by the strain: **Streptococcus** mutans, the vaccine being intranasally administered. The method makes it possible to enhance the yield of Pac and to simplify processes for purifying Pac. The vaccine composition makes it possible to internally easily absorb the protein antigen, Pac, in high efficiency and it also makes it possible to effectively increase the antibody titer observed after the administration thereof.

L13 ANSWER 5 OF 5 USPATFULL

AN 94:24061 USPATFULL

TI **Lactobacillus johnsonii** ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations

IN Mitsuoka, Tomotari, Ichikawa, Japan

Suzuki, Kazumasa, Ayase, Japan

Hayashi, Mitsugu, Hisai, Japan

Doi, Umeyuki, Chita, Japan

Hadeishi, Tsuneo, Chita, Japan

PA Sani-Ei Sucrochemical Co., Ltd., Chita, Japan (non-U.S. corporation)

PI US 5296221 19940322

AI US 1993-51274 19930423 (8)

RLI Continuation of Ser. No. US 1991-768442, filed on 27 Nov 1991, now abandoned

PRAI JP 1990-19100 19900131

DT Utility

EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Ware, Deborah K.

LREP Beveridge, DeGrandi, Weilacher & Young

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1164

AB The present invention comprises a novel strain of **Lactobacillus johnsonii** FERM BP-2680, a lactic acid bacteria preparation using the **Lactobacillus johnsonii** FERM BP-2680, and a process of manufacturing the lactic acid bacteria preparation. The process includes

the steps of inoculating the **Lactobacillus johnsonii** FERM BP-2680 into a medium containing fermentable sugar as a major carbon source, cultivating and proliferating under cultivation conditions adapted to anaerobes or facultative anaerobes, and further isolating

the

**Lactobacillus johnsonii** from the medium and drying the isolated

**Lactobacillus johnsonii** with a protective agent to produce the

lactic acid bacteria preparation. Optionally a bulking agent may be added to control cell concentration of the preparation. The preparation containing **Lactobacillus johnsonii** FERM BP-2680 is used to suppress harmful bacteria in the digestive tract of mammals.